Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PQ7G | ISIN: SE0012853455 | Ticker-Symbol: 6EQ
Tradegate
12.02.26 | 18:47
27,520 Euro
+0,18 % +0,050
1-Jahres-Chart
EQT AB Chart 1 Jahr
5-Tage-Chart
EQT AB 5-Tage-Chart
RealtimeGeldBriefZeit
27,39027,48007:31
27,40027,49007:31
PR Newswire
751 Leser
Artikel bewerten:
(2)

EQT to acquire Europa Biosite, a distributor of life science products

  • EQT Healthcare Growth to acquire Europa Biosite, a distributor of over ten million high-quality life science reagents to academic and biopharma researchers across Europe and North America, from Adelis Equity
  • EQT will support Europa Biosite's next phase of growth through commercial excellence initiatives, digital upgrades, expanded product access, and continued M&A, with the company set to benefit from continued demand for advanced research tools
  • The investment builds on EQT's track record in specialised distribution, including Azelis, Beijer Ref, and OEM International

STOCKHOLM, July 3, 2025 /PRNewswire/ -- EQT Healthcare Growth ("EQT") has agreed to acquire a majority stake in Europa Biosite (or "the Company") - a distributor of high-quality research-use-only (RUO) life science reagents, chemicals, and biological substances used in healthcare R&D - from Adelis Equity. Headquartered in Stockholm, the Company operates in 17 countries across Europe and North America and supports more than 60,000 researchers in academia and biopharma.

Europa Biosite offers access to over ten million individual scientific products essential to life sciences research, such as antibodies, biochemicals, diagnostic kits, and ethically sourced biospecimens, from a wide range of science-led suppliers. It has grown to become a partner for both suppliers and scientists, building on its highly localized footprint and strong technical sales capabilities. The Company serves a fragmented and fast-moving industry, which is expected to benefit from stable research funding.

EQT Healthcare Growth seeks to scale healthcare companies by building commercial muscle and expanding reach, building on EQT's three-decade track record in the healthcare sector. Europa Biosite will draw on this experience to expand its own-brand offering in biospecimens, continue its acquisition strategy to strengthen local market presence and expand to new geographies, and invest in new digital infrastructure. The Company is also set to benefit from EQT's track record in specialized distribution, including Azelis, Beijer Ref, and OEM International, as well as EQT's industrial advisor network, with senior EQT advisor Kate Swann set to lead Europa Biosite's Board.

Rikke Kjær Nielsen, Partner in the EQT Healthcare Growth advisory team, commented: "Europa Biosite supports European scientific research by connecting thousands of labs with the reagents they need to advance discovery. With our support, the company will be set up to scale its business through investments into digital tools, strengthening of its supplier network, and acceleration of its M&A platform. We are proud to support a company that enables critical research and look forward to partnering with Europa Biosite's management team on the next leg of their journey."

"We're excited to partner with EQT for the next phase of growth. With growing demand for reagents and more scientists relying on these critical products, this is a pivotal moment for the business. EQT's expertise in scaling distributors will help us reach new customers, offer even better service, and bring exciting new products to market," said Sune Schmølker, CEO of Europa Biosite.

Kate Swann, Senior Industrial Advisor to EQT, commented: "I am excited to be taking on the role of Chairperson of Europa Biosite and to continue the partnership with EQT. The life sciences sector is vital and fast-moving, and Europa Biosite has a compelling opportunity to grow and contribute to its development. Building on my experience as Chairperson of Beijer Ref, another Swedish specialised distribution business, I look forward to supporting the company's scaling journey."

Contact
EQT Press Office, press@eqtpartners.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/eqt-to-acquire-europa-biosite--a-distributor-of-life-science-products,c4185221

The following files are available for download:

https://mb.cision.com/Main/87/4185221/3550448.pdf

EQT to acquire Europa Biosite, a distributor of life science products

https://news.cision.com/eqt/i/europa-biosite,c3437642

Europa Biosite

Cision View original content:https://www.prnewswire.co.uk/news-releases/eqt-to-acquire-europa-biosite-a-distributor-of-life-science-products-302497511.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.